Genetic Technologies unveils pioneering genomic-based comprehensive risk assessment test
Proactive Investors
Published Mar 22, 2024 12:22
Genetic Technologies unveils pioneering genomic-based comprehensive risk assessment test
Genomics-based testing company Genetic Technologies Limited (ASX:GTG, NASDAQ:GENE, OTC:GNTLF) has made a breakthrough in risk assessment testing for serious diseases with the release of its Comprehensive Risk Assessment Test.
New global standard
Building on the success of its comprehensive Hereditary Breast and Ovarian Cancer (HBOC) test, GTG has introduced an advanced test that encompasses more than 200 high-penetrant genes, setting a new global standard.
The innovation by GeneType, a segment of GTG, is poised to revolutionise the approach to disease risk assessment, covering common cancers, cardiovascular disease, and type 2 diabetes.
This comprehensive test is designed to identify nearly 100% of individuals at risk, extending beyond family history, which accounts for only 5-15% of disease causation.
It also incorporates sporadic non-hereditary diseases, addressing the risk in the remaining 85% of the population.
This non-invasive test is set to impact public health significantly, targeting diseases that account for nearly 70% of annual mortalities and morbidities.
Unprecedented insights
GeneType’s commitment to clinically validated innovation offers unprecedented insights into individual disease risk, enhancing personalised preventative healthcare.
Key features of GeneType's comprehensive risk assessment test include:
- more than 200 high-penetrant genes, offering a thorough assessment of genetic predisposition;
- comprehensive coverage, spanning oncology, cardiovascular, and metabolic diseases, and providing a full spectrum of risk assessment; and
- non-invasive saliva test, ensuring patient accessibility and maintaining high accuracy standards.
The development aligns with the growing demand in the US for advanced genetic testing, where the market was valued at over US$7 billion in 2022.
GTG CEO Simon Morriss said: "As pioneers in risk assessment testing, we are thrilled to introduce our latest GeneType Comprehensive Risk Assessment Test.
“This test empowers individuals to take control of their health and enables healthcare professionals to deliver truly personalised care, resulting in a significant improvement in patient outcomes.”
Read more on Proactive Investors AU
Disclaimer
Get The App
Written By: Proactive Investors
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.